Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review)
- Authors:
- Hongyi Li
- Yu Liu
- Yang Wang
- Xia Zhao
- Xiaorong Qi
-
Affiliations: Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children and Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China - Published online on: August 26, 2021 https://doi.org/10.3892/or.2021.8174
- Article Number: 223
-
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Reid BM, Permuth JB and Sellers TA: Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC and Correa CN: Pathology and classification of ovarian tumors. Cancer. 97 (Suppl 10):S2631–S2642. 2003. View Article : Google Scholar | |
|
Prat J: New insights into ovarian cancer pathology. Ann Oncol. 23 (Suppl 10):x111–x117. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, et al: Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecol Oncol. 151:53–60. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Duska LR and Kohn EC: The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol. 28 (Suppl 8):viii8–viii12. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S and Sehouli J: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 293:695–700. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al: Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 15:668–679. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, et al: Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521:489–494. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, et al: Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget. 6:37663–37677. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wilbur MA, Shih IM, Segars JH and Fader AN: Cancer implications for patients with endometriosis. Semin Reprod Med. 35:110–116. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Munksgaard PS and Blaakaer J: The association between endometriosis and gynecological cancers and breast cancer: A review of epidemiological data. Gynecol Oncol. 123:157–163. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ and Shih IeM: Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 22:1310–1315. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hollis RL and Gourley C: Genetic and molecular changes in ovarian cancer. Cancer Biol Med. 13:236–247. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, Walther A, Zheng J, Fasching P, Zheng W, et al: Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Med. 16:e10028932019. View Article : Google Scholar : PubMed/NCBI | |
|
La Vecchia C: Ovarian cancer: Epidemiology and risk factors. Eur J Cancer Prev. 26:55–62. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liao Y, Tu C, Song X and Cai L: Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. J Assist Reprod Genet. 37:1489–1495. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, et al: Genetic/Familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 19:77–102. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Onwude J: Hormone therapy and ovarian cancer. Lancet. 386:1037–1038. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S and Lidegaard O: Hormone therapy and ovarian cancer. JAMA. 302:298–305. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, et al: ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 30:672–705. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R and Myriokefalitaki E: Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev. 1:CD0125592020.PubMed/NCBI | |
|
Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, et al: Hormone-receptor expression and ovarian cancer survival: An ovarian tumor tissue analysis consortium study. Lancet Oncol. 14:853–862. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Paleari L and DeCensi A: Endocrine therapy in ovarian cancer: Where do we stand? Curr Opin Obstet Gynecol. 30:17–22. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cramer DW and Welch WR: Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 71:717–721. 1983.PubMed/NCBI | |
|
Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E and Persson IR: Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 94:497–504. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez C, Patel AV, Calle EE, Jacob EJ and Thun MJ: Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA. 285:1460–1465. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 90:1774–1786. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Konishi I, Kuroda H and Mandai M: Review: Gonadotropins and development of ovarian cancer. Oncology. 57 (Suppl 2):S45–S48. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A and Hughes C: Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol. 88:554–559. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Goulis DG and Mantzoros CS: Reproductive endocrinology: Novel insights into pathophysiology and clinical management. Metabolism. 86:1–2. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cardenas C, Alvero AB, Yun BS and Mor G: Redefining the origin and evolution of ovarian cancer: A hormonal connection. Endocr Relat Cancer. 23:R411–R422. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Trabert B, Coburn SB, Falk RT, Manson JE, Brinton LA, Gass ML, Kuller LH, Rohan TE, Pfeiffer RM, Qi L, et al: Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study. Cancer Causes Control. 30:1201–1211. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Risch HA, Marrett LD, Jain M and Howe GR: Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol. 144:363–372. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, Hennekens CH and Speizer FE: A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 76:284–290. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD and Myers ER: Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis. J Clin Oncol. 31:4188–4198. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rzepka-Górska I, Chudecka-Głaz A and Kosmowska B: FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Relat Cancer. 11:315–321. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Halperin R, Pansky M, Vaknin Z, Zehavi S, Bukovsky I and Schneider D; Sackler Faculty of Medicine, Tel Aviv University, Israel, : Luteinizing hormone in peritoneal and ovarian cyst fluids: A predictor of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 110:207–210. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chen FC, Oskay-Ozcelik G, Bühling KJ, Köpstein U, Mentze M, Lichtenegger W and Sehouli J: Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer. Anticancer Res. 29:1575–1578. 2009.PubMed/NCBI | |
|
Chudecka-Głaz A and Rzepka-Górska I: Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: Implications for the management of ovarian cancer. Eur J Gynaecol Oncol. 29:37–42. 2008.PubMed/NCBI | |
|
Fathalla MF: Incessant ovulation-a factor in ovarian neoplasia? Lancet. 2:1631971. View Article : Google Scholar : PubMed/NCBI | |
|
Fleming JS, Beaugié CR, Haviv I, Chenevix-Trench G and Tan OL: Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses. Mol Cell Endocrinol. 247:4–21. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fathalla MF: Incessant ovulation and ovarian cancer-a hypothesis re-visited. Facts Views Vis Obgyn. 5:292–297. 2013.PubMed/NCBI | |
|
Peres LC, Moorman PG, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Peters ES, Schwartz AG, et al: Lifetime number of ovulatory cycles and epithelial ovarian cancer risk in African American women. Cancer Causes Control. 28:405–414. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang HP, Murphy KR, Pfeiffer RM, George N, Garcia-Closas M, Lissowska J, Brinton LA and Wentzensen N: Lifetime number of ovulatory cycles and risks of ovarian and endometrial cancer among postmenopausal women. Am J Epidemiol. 183:800–814. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mizushima T and Miyamoto H: The role of androgen receptor signaling in ovarian cancer. Cells. 8:1762019. View Article : Google Scholar : PubMed/NCBI | |
|
Gibson DA, Simitsidellis I, Collins F and Saunders PT: Evidence of androgen action in endometrial and ovarian cancers. Endocr Relat Cancer. 21:T203–T218. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kollara A, Shathasivam P, Park S, Ringuette MJ and Brown TJ: Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation. J Steroid Biochem Mol Biol. 196:1054982020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang SL, Chang TC, Chao CCK and Sun NK: Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells. Biochem Pharmacol. 177:1139652020. View Article : Google Scholar : PubMed/NCBI | |
|
Feng D, Zhao T, Yan K, Liang H, Liang J, Zhou Y, Zhao W and Ling B: Gonadotropins promote human ovarian cancer cell migration and invasion via a cyclooxygenase 2-dependent pathway. Oncol Rep. 38:1091–1098. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Parrott JA, Doraiswamy V, Kim G, Mosher R and Skinner MK: Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol. 172:213–222. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng W, Magid MS, Kramer EE and Chen YT: Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol. 148:47–53. 1996.PubMed/NCBI | |
|
Chambers GM, Sullivan EA, Ishihara O, Chapman MG and Adamson GD: The economic impact of assisted reproductive technology: A review of selected developed countries. Fertil Steril. 91:2281–2294. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pawlikowski Łódź M: Expression of follicle stimulating hormone receptors in intra-tumoral vasculature and in tumoral cells-the involvement in tumour progression and the perspectives of application in cancer diagnosis and therapy. Endokrynol Pol. 69:192–198. 2018.PubMed/NCBI | |
|
Robin B, Planeix F, Sastre-Garau X, Pichon C, Olesen TK, Gogusev J and Ghinea N: Follicle-stimulating hormone receptor expression in endometriotic lesions and the associated vasculature: An immunohistochemical study. Reprod Sci. 23:885–891. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lenhard M, Lennerová T, Ditsch N, Kahlert S, Friese K, Mayr D and Jeschke U: Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology. 58:990–994. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Choi JH, Choi KC, Auersperg N and Leung PC: Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab. 89:5508–5516. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Jia L, Feng Y and Zheng W: Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett. 278:56–64. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Deuster E, Mayr D, Hester A, Kolben T, Zeder-Göß C, Burges A, Mahner S, Jeschke U, Trillsch F and Czogalla B: Correlation of the aryl hydrocarbon receptor with FSHR in ovarian cancer patients. Int J Mol Sci. 20:28622019. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung J, Lokman NA, Abraham RD, Macpherson AM, Lee E, Grutzner F, Ghinea N, Oehler MK and Ricciardelli C: Reduced gonadotrophin receptor expression is associated with a more aggressive ovarian cancer phenotype. Int J Mol Sci. 22:712020. View Article : Google Scholar : PubMed/NCBI | |
|
Lau MT, Wong AS and Leung PC: Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology. 151:2985–2993. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Song K, Dai L, Long X, Wang W and Di W: Follicle-stimulating hormone promotes the proliferation of epithelial ovarian cancer cells by activating sphingosine kinase. Sci Rep. 10:138342020. View Article : Google Scholar : PubMed/NCBI | |
|
Warrenfeltz SW, Lott SA, Palmer TM, Gray JC and Puett D: Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells. Mol Cancer Res. 6:1775–1785. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liao H, Zhou Q, Gu Y, Duan T and Feng Y: Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep. 27:1873–1878. 2012.PubMed/NCBI | |
|
Zhang Z, Liao H, Chen X, Zheng Y, Liu Y, Tao X, Gu C, Dong L, Duan T, Yang Y, et al: Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol. 155:69–74. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sakai T, Shiraishi A, Kawada T, Matsubara S, Aoyama M and Satake H: Invertebrate Gonadotropin-releasing hormone-related peptides and their receptors: An update. Front Endocrinol (Lausanne). 8:2172017. View Article : Google Scholar : PubMed/NCBI | |
|
Jankowska AG, Andrusiewicz M, Fischer N and Warchol PJ: Expression of hCG and GnRHs and their receptors in endometrial carcinoma and hyperplasia. Int J Gynecol Cancer. 20:92–101. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B and Emons G: Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol. 151:141–149. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kang SK, Tai CJ, Cheng KW and Leung PC: Gonadotropin- releasing hormone activates mitogen-activated protein kinase in human ovarian and placental cells. Mol Cell Endocrinol. 170:143–151. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gründker C, Günthert AR, Westphalen S and Emons G: Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol. 146:1–14. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wilkinson SJ, Kucukmetin A, Cross P, Darby S, Gnanapragasam VJ, Calvert AH, Robson CN and Edmondson RJ: Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer. Hum Pathol. 39:1197–1204. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Peng C, Fan NC, Ligier M, Väänänen J and Leung PC: Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology. 135:1740–1746. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Choi KC, Auersperg N and Leung PC: Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab. 86:5075–5078. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Choi JH, Choi KC, Auersperg N and Leung PC: Differential regulation of two forms of gonadotropin-releasing hormone messenger ribonucleic acid by gonadotropins in human immortalized ovarian surface epithelium and ovarian cancer cells. Endocr Relat Cancer. 13:641–651. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KY, Choi KC, Auersperg N and Leung PC: Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: Role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer. 13:211–220. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Padula AM: GnRH analogues-agonists and antagonists. Anim Reprod Sci. 88:115–126. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Limonta P, Marelli MM, Moretti R, Marzagalli M, Fontana F and Maggi R: GnRH in the human female reproductive axis. Vitam Horm. 107:27–66. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Newton CL, Riekert C and Millar RP: Gonadotropin-releasing hormone analog therapeutics. Minerva Ginecol. 70:497–515. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Newton CL, Anderson RC and Millar RP: Therapeutic neuroendocrine agonist and antagonist analogs of hypothalamic neuropeptides as modulators of the hypothalamic-pituitary- gonadal axis. Endocr Dev. 30:106–129. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wuntakal R, Seshadri S, Montes A and Lane G: Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2016:CD0113222016.PubMed/NCBI | |
|
Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L and Moretti RM: GnRH receptors in cancer: From cell biology to novel targeted therapeutic strategies. Endocr Rev. 33:784–811. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gründker C and Emons G: The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis. Front Endocrinol (Lausanne). 8:1872017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Lu ZY, Yan XH, Wang JJ, Feng WW, Ding JX and Hua KQ: Study on the effects of gonadotropin-releasing hormone analogues in the inhibition of ovarian cancer transplanted tumors and in the protection of ovarian function after chemotherapy on nude mice. Zhonghua Fu Chan Ke Za Zhi. 46:892–897. 2011.(In Chinese). PubMed/NCBI | |
|
Völker P, Gründker C, Schmidt O, Schulz KD and Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: Frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol. 186:171–179. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gründker C, Völker P and Emons G: Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology. 142:2369–2380. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Gründker C, Völker P, Schulz KD and Emons G: Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol. 78:194–202. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Engel JB, Hahne JC, Häusler SF, Meyer S, Segerer SE, Diessner J, Dietl J and Honig A: Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells. Anticancer Res. 32:2063–2068. 2012.PubMed/NCBI | |
|
Günthert AR, Gründker C, Hollmann K and Emons G: Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun. 294:11–15. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Imai A, Takagi A, Horibe S, Takagi H and Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 13:97–100. 1998.PubMed/NCBI | |
|
Imai A, Takagi A, Horibe S, Takagi H and Tamaya T: Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: Possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab. 83:427–431. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, Faratian D, Millar RP and Langdon SP: Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation. Endocr Relat Cancer. 20:123–136. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mo Y, Peng P, Zhou R, He Z, Huang L and Yang D: Regulation of gonadotropin-releasing hormone (GnRH) receptor-I expression in the pituitary and ovary by a GnRH agonist and antagonist. Reprod Sci. 17:68–77. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gründker C, Schulz K, Günthert AR and Emons G: Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab. 85:3815–3820. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gründker C, Günthert AR, Millar RP and Emons G: Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab. 87:1427–1430. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Fister S, Günthert AR, Aicher B, Paulini KW, Emons G and Gründker C: GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res. 69:6473–6481. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR and Millar RP: A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology. 144:423–436. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Neill JD, Musgrove LC and Duck LW: Newly recognized GnRH receptors: Function and relative role. Trends Endocrinol Metab. 15:383–392. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gründker C, Huschmand Nia A and Emons G: Gonadotropin- releasing hormone receptor-targeted gene therapy of gynecologic cancers. Mol Cancer Ther. 4:225–231. 2005.PubMed/NCBI | |
|
Parmar H, Phillips RH, Rustin G, Lightman SL and Schally AV: Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (decapeptyl) microcapsules. Biomed Pharmacother. 42:531–538. 1988.PubMed/NCBI | |
|
Jäger W, Wildt L and Lang N: Some observations on the effect of a GnRH analog in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 32:137–148. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Carnino F, Iskra L, Fuda G, Foglia G, Odicino F, Bruzzone M, Chiara S, Gadducci A and Ragni N: The treatment of progressive ovarian carcinoma with D-Trp-LHRH (Decapeptyl). Gruppo Oncologico Nord ovest (GONO). Eur J Cancer. 30A:1903–1904. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Ron IG, Wigler N, Merimsky O, Inbar MJ and Chaitchik S: A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Cancer Invest. 13:272–275. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Duffaud F, van der Burg ME, Namer M, Vergote I, Willemse PH, ten Bokkel Huinink W, Guastalla JP, Nooij, Kerbrat P, Piccart M, et al: D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: An EORTC gynaecological cancer Co-operative group study. Anticancer Drugs. 12:159–162. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Emons G, Ortmann O, Teichert HM, Fassl H, Löhrs U, Kullander S, Kauppila A, Ayalon D, Schally A and Oberheuser F: Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer. 78:1452–1460. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Jager W, Sauerbrei W, Beck E, Maassen V, Stumpfe M, Meier W, Kuhn W and Janicke F: A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res. 15:2639–2642. 1995.PubMed/NCBI | |
|
Sevelda P, Vavra N, Fitz R, Barrada M, Salzer H, Baur M and Dittrich C: Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer. Int J Gynecol Cancer. 2:160–162. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Lind MJ, Cantwell BM, Millward MJ, Robinson A, Proctor M, Simmons D, Carmichael J and Harris AL: A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer. 65:621–623. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E and Jayson GC: Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer. 93:647–651. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Marinaccio M, D'Addario V, Serratì A, Pinto V and Cagnazzo G: Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer. Eur J Gynaecol Oncol. 17:286–288. 1996.PubMed/NCBI | |
|
Paskeviciute L, Roed H and Engelholm S: No rules without exception: Long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol Oncol. 86:297–301. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
du BA, Meier W, Lück HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, et al: Chemotherapy versus hormonal treatment in platinum- and Paclitaxel-refractory ovarian cancer: A randomised trial of the german arbeitsgemeinschaft gynaekologische onkologie (AGO) study group ovarian cancer. Ann Oncol. 13:251–257. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Balbi G, Piano LD, Cardone A and Cirelli G: Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer. 14:799–803. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kavanagh JJ, Roberts W, Townsend P and Hewitt S: Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol. 7:115–118. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Bruckner HW and Motwani BT: Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol. 161:1216–1218. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Miller DS, Brady MF and Barrett RJ: A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 15:125–128. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Völker P, Kavanagh J, Steger M, Schulz KD and Emons G: Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 90:552–559. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Parmar H, Rustin G, Lightman SL, Phillips RH, Hanham IW and Schally AV: Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. Br Med J (Clin Res Ed). 296:12291988. View Article : Google Scholar : PubMed/NCBI | |
|
Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C and Harter P: Efficacy and safety of AEZS-108 (INN: Zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter phase II trial of the ago-study group (AGO GYN 5). Gynecol Oncol. 133:427–432. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Medl M, Peters-Engel C, Fuchs G and Leodolter S: Triptorelin (D-Trp-6-LHRH) in combination with carboplatin-containing polychemotherapy for advanced ovarian cancer: A pilot study. Anticancer Res. 13:2373–2376. 1993.PubMed/NCBI | |
|
Falkson CI, Falkson HC and Falkson G: Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: A pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Oncology. 53:313–317. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Rzepka-Górska I, Chudecka-Glaz A, Kosmider M and Malecha J: GnRH analogues as an adjuvant therapy for ovarian cancer patients. Int J Gynaecol Obstet. 81:199–205. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Mizushima T, Tirador KA and Miyamoto H: Androgen receptor activation: A prospective therapeutic target for bladder cancer? Expert Opin Ther Targets. 21:249–257. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fujii S and Kagechika H: Androgen receptor modulators: A review of recent patents and reports (2012–2018). Expert Opin Ther Pat. 29:439–453. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gucalp A and Traina TA: The androgen receptor: Is it a promising target? Ann Surg Oncol. 24:2876–2880. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ueda T, Mawji NR, Bruchovsky N and Sadar MD: Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem. 277:38087–38094. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pagliarulo V: Androgen deprivation therapy for prostate cancer. Adv Exp Med Biol. 1096:1–30. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rahim B and O'Regan R: AR Signaling in breast cancer. Cancers (Basel). 9:212017. View Article : Google Scholar : PubMed/NCBI | |
|
Antonarakis ES: AR Signaling in human malignancies: Prostate cancer and beyond. Cancers (Basel). 10:222018. View Article : Google Scholar : PubMed/NCBI | |
|
Hamilton TC, Davies P and Griffiths K: Androgen and oestrogen binding in cytosols of human ovarian tumours. J Endocrinol. 90:421–431. 1981. View Article : Google Scholar : PubMed/NCBI | |
|
Kühnel R, de Graaff J, Rao BR and Stolk JG: Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 26:393–397. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC and van der Kwast TH: An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol. 24:90–95. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, Elattar A, Robson CN and Edmondson RJ: Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer. 101:498–503. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C and Castagna G: Androgen receptors in ovarian tumors: Correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res. 17:231–237. 1998.PubMed/NCBI | |
|
Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN and Edmondson RJ: Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. Gynecol Oncol. 124:142–147. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
de Toledo MC, Sarian LO, Sallum LF, Andrade LL, Vassallo J, de Paiva Silva GR, Pinto GA, Soares FA, Fonseca CD and Derchain SF: Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the ‘triple-negative’ tumor status to disease-free and overall survival of women with epithelial ovarian cancer. Acta Histochem. 116:440–447. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jönsson JM, Arildsen NS, Malander S, Måsbäck A, Hartman L, Nilbert M and Hedenfalk I: Sex Steroid hormone receptor expression affects ovarian cancer survival. Transl Oncol. 8:424–433. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Butler MS, Ricciardelli C, Tilley WD and Hickey TE: Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression. Horm Cancer. 4:154–164. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Edmondson RJ, Monaghan JM and Davies BR: The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer. 86:879–885. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Syed V, Ulinski G, Mok SC, Yiu GK and Ho SM: Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 61:6768–6776. 2001.PubMed/NCBI | |
|
Nourbakhsh M, Golestani A, Zahrai M, Modarressi MH, Malekpour Z and Karami-Tehrani F: Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol. 330:10–16. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ligr M, Patwa RR, Daniels G, Pan L, Wu X, Li Y, Tian L, Wang Z, Xu R, Wu J, et al: Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer. PLoS One. 6:e262502011. View Article : Google Scholar : PubMed/NCBI | |
|
Silva EG, Tornos C, Fritsche HA Jr, el-Naggar A, Gray K, Ordonez NG, Luna M and Gershenson D: The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: A potential animal model. Mod Pathol. 10:879–883. 1997.PubMed/NCBI | |
|
Sawada M, Terada N, Wada A, Mori Y, Yamasaki M, Saga T and Endo K: Estrogen- and androgen-responsive growth of human ovarian adenocarcinoma heterotransplanted into nude mice. Int J Cancer. 45:359–363. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Park BY, Grisham RN, den Hollander B, Thapi D, Berman T, de Stanchina E, Zhou Q, Iyer G, Aghajanian C and Spriggs DR: Tumor Inhibition by Enzalutamide in a xenograft model of ovarian cancer. Cancer Invest. 34:517–520. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Proverbs-Singh T, Feldman JL, Morris MJ, Autio KA and Traina TA: Targeting the androgen receptor in prostate and breast cancer: Several new agents in development. Endocr Relat Cancer. 22:R87–R106. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun NK, Huang SL, Chang PY, Lu HP and Chao CC: Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response. Oncotarget. 5:11939–11956. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sun NK, Huang SL, Lu HP, Chang TC and Chao CC: Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor. Oncotarget. 6:27065–27082. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tumolo S, Rao BR, van der Burg ME, Guastalla JP, Renard J and Vermorken JB: Phase II trial of flutamide in advanced ovarian cancer: An EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer. 30A:911–914. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Vassilomanolakis M, Koumakis G, Barbounis V, Hajichristou H, Tsousis S and Efremidis A: A phase II study of flutamide in ovarian cancer. Oncology. 54:199–202. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Gruessner C, Gruessner A, Glaser K, AbuShahin N, Zhou Y, Laughren C, Wright H, Pinkerton S, Yi X, Stoffer J, et al: Flutamide and biomarkers in women at high risk for ovarian cancer: Preclinical and clinical evidence. Cancer Prev Res (Phila). 7:896–905. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, et al: A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer. 110:2448–2456. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Grisham RN, Giri DD, Iasonos A, Zhou Q, Girshman J, McGrath SP, O'Cearbhaill RE, Sabbatini P, Tew WP, Michael Hyman D, et al: A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies. J Clin Oncol. 35 (Suppl 15):TPS56102017. View Article : Google Scholar | |
|
Miyamoto H, Messing EM and Chang C: Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate. 61:332–353. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 324:787–790. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fuentes N and Silveyra P: Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 116:135–170. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Björnström L and Sjöberg M: Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl Recept. 2:32004. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar A and Foster TC: G Protein-Coupled estrogen receptor: Rapid effects on hippocampal-dependent spatial memory and synaptic plasticity. Front Endocrinol (Lausanne). 11:3852020. View Article : Google Scholar : PubMed/NCBI | |
|
O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF and Langdon SP: Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer. 12:851–866. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Arnal JF, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M, Fontaine C, Gourdy P, Chambon P, Katzenellenbogen B and Katzenellenbogen J: Membrane and nuclear estrogen receptor alpha actions: From tissue specificity to medical implications. Physiol Rev. 97:1045–1087. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ghasemi A, Saeidi J, Mohtashami M and Hashemy SI: Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis. Mol Cell Biochem. 458:207–217. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bogush TA, Basharina AA, Bogush EA, Ryabinina OM, Tjulandina AS and Tjulandin SA: Estrogen receptors alpha and beta in ovarian cancer: Expression level and prognosis. Dokl Biochem Biophys. 482:249–251. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Andersen CL, Sikora MJ, Boisen MM, Ma T, Christie A, Tseng G, Park Y, Luthra S, Chandran U, Haluska P, et al: Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens. Clin Cancer Res. 23:3802–3812. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN and Ngan HY: Estrogen receptor subtypes in ovarian cancer: A clinical correlation. Obstet Gynecol. 111:144–151. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, Jacquard C, Pillon A, Balaguer P, Balabanian K and Lazennec G: Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One. 7:e447872012. View Article : Google Scholar : PubMed/NCBI | |
|
Rutherford T, Brown WD, Sapi E, Aschkenazi S, Muñoz A and Mor G: Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol. 96:417–421. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Hoffmann M, Gogola J and Ptak A: Apelin abrogates the stimulatory effects of 17β-estradiol and insulin-like growth factor-1 on proliferation of epithelial and granulosa ovarian cancer cell lines via crosstalk between APLNR and ERα/IGF1R. Mol Biol Rep. 46:6325–6338. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Yan Y, Wen H, Jiang X, Cao X, Zhang G and Liu G: A novel estrogen receptor GPER mediates proliferation induced by 17β-estradiol and selective GPER agonist G-1 in estrogen receptor α (ERα)-negative ovarian cancer cells. Cell Biol Int. 38:631–638. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chan KK, Leung TH, Chan DW, Wei N, Lau GT, Liu SS, Siu MK and Ngan HY: Targeting estrogen receptor subtypes (ERalpha and ERbeta) with selective ER modulators in ovarian cancer. J Endocrinol. 221:325–336. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Park SH, Cheung LW, Wong AS and Leung PC: Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol. 22:2085–2098. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H and Pujol P: Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene. 21:1097–1107. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ciucci A, Zannoni GF, Travaglia D, Scambia G and Gallo D: Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer. Hum Pathol. 46:1138–1146. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kyriakidis I and Papaioannidou P: Estrogen receptor beta and ovarian cancer: A key to pathogenesis and response to therapy. Arch Gynecol Obstet. 293:1161–1168. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lazennec G: Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett. 231:151–157. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G and Ortmann O: Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol. 193:421–433. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Rao Tekmal R, Li R, Rao MK, Curiel T, et al: Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer. Oncotarget. 8:50002–50014. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chan KKL, Siu MKY, Jiang YX, Wang JJ, Wang Y, Leung THY, Liu SS, Cheung ANY and Ngan HYS: Differential expression of estrogen receptor subtypes and variants in ovarian cancer: Effects on cell invasion, proliferation and prognosis. BMC Cancer. 17:6062017. View Article : Google Scholar : PubMed/NCBI | |
|
Chan KKL, Siu MKY, Jiang YX, Wang JJ, Leung THY and Ngan HYS: Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer. Cancer Cell Int. 18:652018. View Article : Google Scholar : PubMed/NCBI | |
|
Fekete T, Rásó E, Pete I, Tegze B, Liko I, Munkácsy G, Sipos N, Rigó J Jr and Györffy B: Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int J Cancer. 131:95–105. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schüler-Toprak S, Weber F, Skrzypczak M, Ortmann O and Treeck O: Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer. BMC Cancer. 18:9812018. View Article : Google Scholar : PubMed/NCBI | |
|
Fujimoto J, Hirose R, Sakaguchi H and Tamaya T: Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers. Oncology. 58:334–341. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, de Vries E, Hospers G and Reyners A: Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol. 138:634–639. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
van der Vange N, Greggi S, Burger CW, Kenemans P and Vermorken JB: Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol. 34:813–820. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Rolski J and Pawlicki M: Evaluation of efficacy and toxicity of tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Ginekol Pol. 69:586–589. 1998.(In Polish). PubMed/NCBI | |
|
Tropé C, Marth C and Kaern J: Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur J Cancer. 36 (Suppl 4):S59–S61. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Van Der Velden J, Gitsch G, Wain GV, Friedlander ML and Hacker NF: Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 5:301–305. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D, et al: Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-atlantic oncology program. J Clin Oncol. 11:1957–1968. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Jakobsen A, Bertelsen K and Sell A: Cyclic hormonal treatment in ovarian cancer. A phase-II trial. Eur J Cancer Clin Oncol. 23:915–916. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Pagel J RC and Thorpe S: Treatment of advanced ovarian carcinoma with tamoxifen: A phase II trial. Proc 2nd Eur Conf Clin Oncol. May 29–1983.(Epub ahead of print). | |
|
Osborne RJ, Malik ST, Slevin ML, Harvey VJ, Spona J, Salzer H and Williams CJ: Tamoxifen in refractory ovarian cancer: The use of a loading dose schedule. Br J Cancer. 57:115–116. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Slevin ML, Harvey VJ, Osborne RJ, Shepherd JH, Williams CJ and Mead GM: A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol. 22:309–312. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Shirey DR, Kavanagh JJ Jr, Gershenson DM, Freedman RS, Copeland LJ and Jones LA: Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol. 66:575–578. 1985.PubMed/NCBI | |
|
Hatch KD, Beecham JB, Blessing JA and Creasman WT: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 68:269–271. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Weiner SA, Alberts DS, Surwit EA, Davis J and Grosso D: Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol. 27:208–213. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Schwartz PE, Keating G, MacLusky N, Naftolin F and Eisenfeld A: Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol. 59:583–588. 1982.PubMed/NCBI | |
|
George A, McLachlan J, Tunariu N, Della Pepa C, Migali C, Gore M, Kaye S and Banerjee S: The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: A retrospective series of tamoxifen and letrozole. BMC Cancer. 17:4562017. View Article : Google Scholar : PubMed/NCBI | |
|
Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K and Benbrook DM: Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 119:444–450. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Schwartz PE, Chambers JT, Kohorn EI, Chambers SK, Weitzman H, Voynick IM, MacLusky N and Naftolin F: Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer. 63:1074–1078. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Panici PB, Greggi S, Amoroso M, Scambia G, Battaglia FA, Gebbia V, Salerno G, Paratore MP and Mancuso S: A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: Results of a Phase II study. Int J Gynecol Cancer. 11:438–444. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Markman M, Webster K, Zanotti K, Peterson G, Kulp B and Belinson J: Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol. 94:404–408. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück HJ, Sehouli J, Gropp M, Stähle A, Schmalfeldt B, et al: Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol. 105:132–137. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A and Smyth JF: CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin Cancer Res. 8:2233–2239. 2002.PubMed/NCBI | |
|
Colon-Otero G, Weroha SJ, Foster NR, Haluska P, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW and Copland JA: Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecol Oncol. 146:64–68. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M and Seiden MV: Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 91:596–602. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kavanagh JJ, Hu W, Fu S, Deavers M, Moore C, Coleman RL, Levenback CF, Shen D, Zheng HG, YF Y, et al: Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors. J Clin Oncol. 25 (Suppl 18):S55822007. View Article : Google Scholar : PubMed/NCBI | |
|
Krasner CN, Debernardo RL, Findley M, Penson R, Matulonis U, Atkinson T, Roche M and Seiden MV: Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. J Clin Oncol. 23 (Suppl 16):S50632005. View Article : Google Scholar | |
|
Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M and Dimopoulos MA: Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 66:112–117. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL and Gershenson DM: Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 110:56–59. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, et al: Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 13:3617–3622. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tchekmedyian NS, Liem AK, Quan ET, Burtzo DM and Ucar K: Aromatase inhibitor therapy for estrogen receptor positive ovarian cancer. J Clin Oncol. 24 (Suppl 18):S150382006. View Article : Google Scholar : PubMed/NCBI | |
|
Verma S, Alhayki M, Le T, Baines K, Rambout L, Hopkins L and Fung Kee Fung M: Phase II study of exemestane (E) in refractory ovarian cancer (ROC). J Clin Oncol. 24 (Suppl 18):S50262006. View Article : Google Scholar | |
|
Williams C, Simera I and Bryant A: Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2010:CD0010342010.PubMed/NCBI | |
|
Perez-Gracia JL and Carrasco EM: Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research. Gynecol Oncol. 84:201–209. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Paleari L, Gandini S, Provinciali N, Puntoni M, Colombo N and DeCensi A: Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. Gynecol Oncol. 146:504–513. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kok PS, Beale P, O'Connell RL, Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, et al: PARAGON (ANZGOG-0903): A phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. J Gynecol Oncol. 30:e862019. View Article : Google Scholar : PubMed/NCBI | |
|
Stanley B, Hollis RL, Nunes H, Towler JD, Yan X, Rye T, Dawson C, Mackean MJ, Nussey F, Churchman M, et al: Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. Gynecol Oncol. 152:278–285. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A and Sun CC: Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol. 35:1103–1111. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fader AN, Bergstrom J, Jernigan A, Tanner EJ III, Roche KL, Stone RL, Levinson KL, Ricci S, Wethingon S, Wang TL, et al: Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol. 147:85–91. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, et al: Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 156:715–725. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang A, Curtin J and Muggia F: Ovarian adult-type granulosa cell tumor: Focusing on endocrine-based therapies. Int J Endocrine Oncol. 52018.doi: 10.2217/ije-2017-0021. PubMed/NCBI | |
|
van Meurs HS, van Lonkhuijzen LR, Limpens J, van der Velden J and Buist MR: Hormone therapy in ovarian granulosa cell tumors: A systematic review. Gynecol Oncol. 134:196–205. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Graham JD and Clarke CL: Physiological action of progesterone in target tissues. Endocr Rev. 18:502–519. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Diep CH, Daniel AR, Mauro LJ, Knutson TP and Lange CA: Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol. 54:R31–R53. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mesiano S, Wang Y and Norwitz ER: Progesterone receptors in the human pregnancy uterus: Do they hold the key to birth timing? Reprod Sci. 18:6–19. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Conneely OM, Mulac-Jericevic B and Lydon JP: Progesterone- dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids. 68:771–778. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Diep CH, Charles NJ, Gilks CB, Kalloger SE, Argenta PA and Lange CA: Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle. 12:1433–1449. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, Moriya T, Okamura K, Yajima A and Sasano H: Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: Immunohistochemical and RT-PCR studies. Br J Cancer. 83:1488–1494. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Akahira J, Suzuki T, Ito K, Kaneko C, Darnel AD, Moriya T, Okamura K, Yaegashi N and Sasano H: Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res. 93:807–815. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, Friese K and Jeschke U: Steroid hormone receptor expression in ovarian cancer: Progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 12:5532012. View Article : Google Scholar : PubMed/NCBI | |
|
Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD and Myers ER: Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. Obstet Gynecol. 122:139–147. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara CM, Myrtveit Saether SM, Sköld C, Sørensen HT, Trabert B and Glimelius I: The role of pregnancy, perinatal factors and hormones in maternal cancer risk: A review of the evidence. J Intern Med. 283:430–445. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Han KH, Kim MK, Kim HS, Chung HH and Song YS: Protective effect of progesterone during pregnancy against ovarian cancer. J Cancer Prev. 18:113–122. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Eisenhofer G, Peitzsch M, Kaden D, Langton K, Pamporaki C, Masjkur J, Tsatsaronis G, Mangelis A, Williams TA, Reincke M, et al: Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clin Chim Acta. 470:115–124. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ji J, Försti A, Sundquist J and Hemminki K: Risks of breast, endometrial, and ovarian cancers after twin births. Endocr Relat Cancer. 14:703–711. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Peluso JJ: Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids. 76:903–909. 2011.PubMed/NCBI | |
|
Wu NY, Huang HS, Chao TH, Chou HM, Fang C, Qin CZ, Lin CY, Chu TY and Zhou HH: Progesterone prevents high-grade serous ovarian cancer by inducing necroptosis of p53-defective fallopian tube epithelial cells. Cell Rep. 18:2557–2565. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pelegrina LT, de Los Ángeles Sanhueza M, Ramona Cáceres AR, Cuello-Carrión D, Rodriguez CE and Laconi MR: Effect of progesterone and first evidence about allopregnanolone action on the progression of epithelial human ovarian cancer cell lines. J Steroid Biochem Mol Biol. 196:1054922020. View Article : Google Scholar : PubMed/NCBI | |
|
McGlorthan L, Paucarmayta A, Casablanca Y, Maxwell GL and Syed V: Progesterone induces apoptosis by activation of caspase-8 and calcitriol via activation of caspase-9 pathways in ovarian and endometrial cancer cells in vitro. Apoptosis. 26:184–194. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xie YL, Yang YJ, Tang C, Sheng HJ, Jiang Y, Han K and Ding LJ: Estrogen combined with progesterone decreases cell proliferation and inhibits the expression of Bcl-2 via microRNA let-7a and miR-34b in ovarian cancer cells. Clin Transl Oncol. 16:898–905. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JY, Shin JY, Kim HS, Heo JI, Kho YJ, Kang HJ, Park SH and Lee JY: Effect of combined treatment with progesterone and tamoxifen on the growth and apoptosis of human ovarian cancer cells. Oncol Rep. 27:87–93. 2012.PubMed/NCBI | |
|
Shin YY, Kang EJ, Jeong JS, Kim MJ, Jung EM, Jeung EB and An BS: Pregnenolone as a potential candidate for hormone therapy for female reproductive disorders targeting ERβ. Mol Reprod Dev. 86:109–117. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pedernera E, Gómora MJ, Morales-Vásquez F, Pérez-Montiel D and Mendez C: Progesterone reduces cell survival in primary cultures of endometrioid ovarian cancer. J Ovarian Res. 12:152019. View Article : Google Scholar : PubMed/NCBI | |
|
Peluso JJ, Liu X, Saunders MM, Claffey KP and Phoenix K: Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab. 93:1592–1599. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gamarra-Luques CD, Goyeneche AA, Hapon MB and Telleria CM: Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer. 12:2002012. View Article : Google Scholar : PubMed/NCBI | |
|
Gamarra-Luques CD, Hapon MB, Goyeneche AA and Telleria CM: Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity. J Ovarian Res. 7:452014. View Article : Google Scholar : PubMed/NCBI | |
|
Telleria CM: Repopulation of ovarian cancer cells after chemotherapy. Cancer Growth Metastasis. 6:15–21. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mangioni C, Franceschi S, Vecchia CL and D'Incalci M: High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy. Gynecol Oncol. 12:314–318. 1981. View Article : Google Scholar : PubMed/NCBI | |
|
Slayton RE, Pagano M and Creech RH: Progestin therapy for advanced ovarian cancer: A phase II Eastern Cooperative Oncology Group trial. Cancer Treat Rep. 65:895–896. 1981.PubMed/NCBI | |
|
Aabo K, Pedersen AG, Haid I and Dombernowsky P: High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: A phase II study. Cancer Treat Rep. 66:407–408. 1982.PubMed/NCBI | |
|
Tropé C, Johnsson JE, Sigurdsson K and Simonsen E: High-dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma. Cancer Treat Rep. 66:1441–1443. 1982.PubMed/NCBI | |
|
Hamerlynck JV, Maskens AP, Mangioni C, van der Burg ME, Wils JA, Vermorken JB and Rotmensz N: Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC Gynecological Cancer Cooperative Group Study. Gynecol Oncol. 22:313–316. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Malfetano J, Beecham JB, Bundy BN and Hatch KD: A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers. A Gynecologic Oncology Group study. Am J Clin Oncol. 16:149–151. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Geisler HE: The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma. Semin Oncol. 12 (Suppl 1):S20–S22. 1985. | |
|
Sikic BI, Scudder SA, Ballon SC, Soriero OM, Christman JE, Suey L, Ehsan MN, Brandt AE and Evans TL: High-dose megestrol acetate therapy of ovarian carcinoma: A phase II study by the Northern California Oncology Group. Semin Oncol. 13 (Suppl 4):S26–S32. 1986.PubMed/NCBI | |
|
Belinson JL, McClure M and Badger G: Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol. 28:151–155. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Veenhof CH, van der Burg ME, Nooy M, Aalders JG, Pecorelli S, Oliveira CF, Rotmensz N and Vermorken JB: Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur J Cancer. 30A:697–698. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Wiernik PH, Greenwald ES, Ball H, Young JA and Vogl S: High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884. Am J Clin Oncol. 21:565–567. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Wilailak S, Linasmita V and Srisupundit S: Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. Anticancer Drugs. 12:719–724. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Rocereto TF, Saul HM, Aikins JA Jr and Paulson J: Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol. 77:429–432. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J and Mannel RS: A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study. Gynecol Oncol. 116:332–334. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Niwa K, Onogi K, Wu Y, Mori H, Harrigan RC and Tamaya T: Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: A pilot study. Eur J Gynaecol Oncol. 29:252–255. 2008.PubMed/NCBI | |
|
Zheng H, Kavanagh JJ, Hu W, Liao Q and Fu S: Hormonal therapy in ovarian cancer. Int J Gynecol Cancer. 17:325–338. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M and Greggi S: Conservative treatment of early endometrial cancer: Preliminary results of a pilot study. Gynecol Oncol. 120:43–46. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bonaventura A, O'Connell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, et al: Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptor-positive platinum-resistant or -refractory recurrent ovarian cancer. Int J Gynecol Cancer. 27:900–906. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Freedman RS, Saul PB, Edwards CL, Jolles CJ, Gershenson DM, Jones LA, Atkinson EN and Dana WJ: Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma: A phase II study. Cancer Treat Rep. 70:369–373. 1986.PubMed/NCBI | |
|
Greiser CM, Greiser EM and Dören M: Menopausal hormone therapy and risk of ovarian cancer: Systematic review and meta-analysis. Hum Reprod Update. 13:453–463. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Beral V, Bull D, Green J and Reeves G: Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 369:1703–1710. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Koskela-Niska V, Lyytinen H, Riska A, Pukkala E and Ylikorkala O: Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy-a nationwide study. Climacteric. 16:48–53. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Danforth KN, Park Y and Brinton LA: Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer. 107:1181–1187. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Morch LS, Lokkegaard E, Andreasen AH, Kjaer SK and Lidegaard O: Hormone therapy and different ovarian cancers: A national cohort study. Am J Epidemiol. 175:1234–1242. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Ma L, Yang X, Bie J, Li D, Sun C, Zhang J, Meng Y and Lin J: Menopausal hormone replacement therapy and the risk of ovarian cancer: A meta-analysis. Front Endocrinol (Lausanne). 10:8012019. View Article : Google Scholar : PubMed/NCBI | |
|
Beral V, Gaitskell K, Hermon C, Moser K, Reeves G and Peto R: Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. Lancet. 385:1835–1842. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wen Y, Huang H, Huang H, Wu M, Shen K and Pan L: The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China. Climacteric. 16:673–681. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li D, Ding CY and Qiu LH: Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis. Gynecol Oncol. 139:355–362. 2015. View Article : Google Scholar : PubMed/NCBI |
